Group 7 Copy 3 Created with Sketch.
News Issue Archive Device Guide Calendar Subscribe Advertising

MENU

Centers

Carotid Coding Dialysis Embolization EVAR HTN Limb Salvage Neurointervention Oncology Radial Regulatory Renal SFA TEVAR Venous

News Current Issue Archive Device Guide Calendar Subscribe Advertising About Contact Privacy Submissions
Carotid Coding Dialysis Embolization EVAR HTN Limb Salvage Neurointervention Oncology Radial Regulatory Renal SFA TEVAR Venous

Advertisement

Advertisement

Search Results

Show Filters

close Created with Sketch.

Refine by Content Type

close Created with Sketch.

Refine by Year

close Created with Sketch.

Advertisement

Sort By:

Relevance Date

Choose Sites to Search:

EVToday EVToday + CIToday

evt | Article | November 2008

An Interview With Daniel Clair, MD

The Department Chair of Vascular Surgery at the Cleveland Clinic discusses the role of embolic protection devices and the potential impact of CMS's decision not to expand reimbursement for CAS.

evt | Article | September 2021

Panel Discussion: CFA Disease: Exploring Options in a Typically Surgical Indication

Moderator Peter A. Schneider, MD, asks Daniela Branzan, MD; Daniel Clair, MD; Tony Das, MD, FACC; and Yann Gouëffic, MD, PhD, about their approaches to CFA lesions, patient and clinical factors they consider, data that support an endovascular approach, preferred tools and rules of thumb, and how treatment of CFA disease looks in the future.

Sponsored by LimFlow, Inc.

evt | Article | May 2021

LimFlow Percutaneous Deep Venous Arterialization

Trial data updates and experiences with latest-generation techniques and technologies.

With Daniel Clair, MD; Mehdi H. Shishehbor, DO, MPH, PhD; Jorge Martínez Trabal, MD, FACS, RPVI; Michiel Schreve, MD; Miguel Montero-Baker, MD; Brian Lepow, DPM; and Roberto Ferraresi, MD

evt | Article | August 2024

Efficiency in Carotid Revascularization Inventory and Instrumentation

Techniques and considerations for a patient-centered approach to carotid revascularization with CEA, TFCAS, and TCAR.

By Daniel Clair, MD, and Ziad Al Adas, MD

Advertisement

Advertisement

Sponsored by Inari LimFlow

evt | Article | February 2024 Supplement

How Will TADV Change Clinical Practice?

TADV can offer no-option patients hope for limb preservation and will become part of the armamentarium for vascular specialists.

By Daniel Clair, MD

Sponsored by LimFlow, Inc.

evt | Article | May 2020

The Evolving Role of Percutaneous Deep Venous Arterialization

Considerations on the challenge of no-option CLTI, patient candidacy, and clinical experiences to date.

With Daniel Clair, MD; Roberto Ferraresi, MD; Andrej Schmidt, MD; Steven Kum, MD; and Mehdi Shishehbor, DO, MPH, PhD

Sponsored by Inari LimFlow

evt | Article | February 2024 Supplement

Q&A: PROMISE II Experience and Data Overview

Coprincipal Investigators from PROMISE II discuss the uniqueness of the recently published study, patient population characteristics, key highlights from the data, and more.

With Daniel Clair, MD, and Mehdi H. Shishehbor, DO, MPH, PhD

evt | Article | January 2023

Panel Discussion: Perspectives on Applying BEST-CLI in Practice

Experts discuss the study’s findings, its strengths and limitations, and clinical implications, as well as lessons learned regarding optimal medical therapy and what needs to be explored further.

With Daniel Clair, MD; Sanjay Misra, MD; Leigh Ann O'Banion, MD; and Mehdi H. Shishehbor, DO, MPH, PhD

evt | News | November 6, 2020

Safety and Efficacy of LimFlow’s pDVA System Evaluated in PROMISE I Trial

November 6, 2020—Daniel Clair, MD, presented findings from the multicenter PROMISE I trial of the first human use in the United States of the LimFlow system (LimFlow SA), a purpose-built percutaneous deep vein arterialization (pDVA) device for the treatment of no-option chronic limb-threatening ischemia (CLTI) patients.

evt | News | October 6, 2021

LimFlow Deep Vein Arterialization System to Treat CLTI Evaluated in 2-Year PROMISE I Data

October 6, 2021—Daniel Clair, MD, presented 2-year results from the PROMISE I trial, which is evaluating the LimFlow system (LimFlow SA) for creating deep vein arterialization in the treatment of patients with severe, unreconstructable chronic limb-threatening ischemia (CLTI).

evt | News | January 15, 2012

Nine-Month ORION Data Support Boston Scientific's Epic Stent to Treat Iliac Disease

January 16, 2012—Boston Scientific Corporation (Natick, MA) announced that Principal Investigator Daniel Clair, MD, presented 9-month clinical endpoint data from the company's ORION trial at the International Symposium on Endovascular Therapy (ISET) in Miami Beach, Florida.

evt | News | November 5, 2024

PROMISE II Trial Evaluates TADV With Inari’s LimFlow System

November 5, 2024—Two-year outcomes from the PROMISE II trial assessed transcatheter arterialization of the deep veins (TADV) using the LimFlow System (Inari Medical).

evt | News | November 4, 2019

Endospan's Nexus Arch Branch Stent Graft System Studied at 2 Years

November 5, 2019—VIVA Physicians announced that 2-year results from a prospective, multicenter, premarket study composed of 25 patients (mean age, 73 years) treated with the Nexus aortic arch stent graft (Endospan) were presented by Daniel Clair, MD, in a late-breaking clinical trial session at VIVA 2019, the Vascular InterVentional Advances meeting held November 4–7 in Las Vegas, Nevada.

evt | News | November 5, 2019

Six-Month Data From PROMISE I Presented for LimFlow System to Treat CLTI

November 6, 2019—LimFlow SA announced the presentation of positive 6-month data from the full patient cohort in the PROMISE I early feasibility study of the LimFlow percutaneous deep vein arterialization system.

evt | News | October 22, 2012

ORION 12-Month Data Support Boston Scientific's Epic Stent for Iliac Artery Disease

October 23, 2012—Boston Scientific Corporation (Natick, MA) announced that 12-month clinical endpoint data from the ORION trial demonstrated the safety and effectiveness of the Epic self-expanding nitinol stent system in patients with obstructed iliac arteries.

evt | News | September 30, 2025

FastWave Names Leadership for Pivotal Trial of Artero Electric IVL System

September 30, 2025—FastWave Medical, a developer of intravascular lithotripsy (IVL), announced the appointment of the principal investigators and steering committee for the upcoming United States investigational device exemption pivotal trial of the company’s Artero peripheral electric IVL system.

evt | News | October 31, 2023

LimFlow System for TADV in CLTI Evaluated at 1 Year in PROMISE II Pivotal Trial

October 31, 2023—The 1-year results of the multicenter PROMISE II pivotal trial of the purpose-built LimFlow system (LimFlow, Inc.) for transcatheter arterialization of deep veins (TADV) evaluated the device in the treatment of patients with no-option chronic limb-threatening ischemia (CLTI) patients.

evt | News | January 9, 2011

Boston Scientific Completes Enrollment in ORION Trial of Epic Stent to Treat Iliac Disease

January 10, 2011—Boston Scientific Corporation (Natick, MA) announced the completion of enrollment in the ORION clinical trial, which is designed to evaluate the company's Epic self-expanding nitinol stent system for the treatment of iliac artery disease.

evt | News | November 4, 2022

LimFlow System’s 6-Month Outcomes Presented From the PROMISE II US Pivotal Trial

November 4, 2022—Six-month results from the PROMISE II United States pivotal trial of transcatheter arterialization of the deep veins with the LimFlow system (LimFlow, Inc.) showed that outcomes were better than expected and reproducible, and that the study’s “no-option” patient population can significantly benefit from this procedure.

evt | News | March 30, 2023

LimFlow System’s PROMISE II Pivotal Trial Results Published

March 30, 2023—LimFlow SA, a developer of minimally invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), announced the publication of results from the PROMISE II United States pivotal trial that demonstrated the LimFlow system achieved a 66% rate of amputation-free survival at 6 months.


1
2
3
4

Advertisement

Advertisement

Carotid Coding Dialysis Embolization EVAR HTN Limb Salvage Neurointervention Oncology Radial Regulatory Renal SFA TEVAR Venous
Centers

Carotid Coding Dialysis Embolization EVAR HTN Limb Salvage Neurointervention Oncology Radial Regulatory Renal SFA TEVAR Venous

News• Current Issue• Archive• Device Guide• Advertising• About Calendar• Contact• Privacy• Submissions• Subscriptions


Endovascular Today (ISSN 1551-1944 print and ISSN 2689-792X online) is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field.



magazine Created with Sketch.

Free Print Subscriptions

Fill 1 Created with Sketch.

Email Newsletter



twitter-icon LinkedIn Created with Sketch. instagram BlueSky-Circle
Cardiac Interventions Today
Group 7 Copy 3 Created with Sketch.
bmc-secondary-mark-color copy Created with Sketch.

© 2026 Bryn Mawr Communications II, LLC.  
All Rights Reserved   •   Privacy Policy

one-trust-button